PT-141 (bremelanotide) is a melanocortin receptor agonist, combined here with oxytocin in a gum formulation. The combination is studied for its role in melanocortin and oxytocin receptor signaling and the associated neuroendocrine pathways.

This gum formulation is used in controlled laboratory workflows and investigative settings examining melanocortin and oxytocin receptor activity, neuroendocrine signaling, and behavior-related mechanisms. It is applied in structured research models characterizing receptor activity and downstream pathway interactions.

The combination supports analytical studies and cell-based models involving melanocortin receptor agonism, oxytocin-mediated signaling, arousal-related pathways, and neuroendocrine cross-talk. It is relevant for pathway characterization and assay development focused on behavioral and hormonal mechanisms within controlled study frameworks.

PT-141 + Oxytocin Gum is suited for researchers and investigators studying melanocortin and oxytocin receptor signaling and related neuroendocrine mechanisms within controlled study frameworks.